SynthesisIndian pediatrics2025
Cerebrospinal Procalcitonin for Diagnosing Meningitis in Infants Less Than 90 Days: A Systematic Review and Meta-analysis.
Synthesis in Indian pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextEarly identification and treatment of meningitis in early infancy is crucial for improved outcomes. However, the commonly used cerebrospinal fluid (CSF) markers for diagnosing meningitis have poor diagnostic accuracy.
objectiveTo assess the diagnostic utility of CSF procalcitonin for diagnosing meningitis in infants with postnatal age less than 90 days. EVIDENCE ACQUISITION: We searched databases, including MEDLINE, Embase, and Scopus, from inception to 15 March 2025. We included observational studies that used CSF procalcitonin as a marker for diagnosing meningitis in infants with a postnatal age of less than 90 days. The risk of bias was assessed using the QUADAS-2, and the certainty of evidence was ascertained using GRADE approach. The bivariate random effect model and hierarchical summary receiver operating characteristic meta-analysis were used to pool data with multiple thresholds.
resultsOut of 815 retrieved records, seven studies involving 963 infants were included in the meta-analysis. We obtained diagnostic accuracy measures at commonly used threshold cut-offs of 0.20 ng/mL and 0.33 ng/mL. At a CSF procalcitonin threshold cut-off of 0.20 ng/mL, the pooled sensitivity (95%CI) was 77.1% (49.2%, 92.1%), and the pooled specificity (95%CI) was 68.9% (49.2%, 83.5%). At a cut-off of 0.33 ng/mL, sensitivity was 75.8% (50.1%, 90.7%) and specificity was 75.1% (58.5%, 86.6%). The certainty of evidence remained very low for both sensitivity and specificity.
conclusionCSF procalcitonin has moderate sensitivity and specificity for diagnosing meningitis in infants with postnatal age < 90 days. However, wide confidence intervals and very low certainty of evidence limit the reliability of these findings.
Indexed as
Identifiers
41060555What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.